

Special Issue

Cardiac Complications and Cardiotoxicity of Radiation Therapy

Message from the Guest Editors

Radiation therapy improves locoregional tumor control and the overall survival of patients with solid tumors, such as breast, lung, and esophageal cancers, and Hodgkin's lymphoma. Although the benefits of radiation therapy far outweigh the risk of developing subsequent cardiovascular diseases, there is ongoing debate regarding the safest radiation dose, which cardiac substructures are most sensitive to radiotherapy, and the most appropriate strategies for prevention. The aim of this Special Issue is to provide an overview and new elements concerning the mentioned current debate on the cardiovascular complications and cardiotoxicity of radiation therapy. This could be covered by large epidemiological studies, clinical studies with advanced imaging and diagnostic techniques, and radiation dosimetry research, but also through radiobiological and mechanistic studies, as well as review articles.

Guest Editors

Dr. Sophie Jacob

Prof. Dr. Carlo De Asmundis

Prof. Dr. Juliette Thariat

Deadline for manuscript submissions

closed (30 November 2023)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/153927

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).